ACG President’s Plenary to Showcase Study on Xifaxan(R) (rifaximin) Reducing Risk of Overt Hepatic Encephalopathy (OHE) Recurrence
Bausch Health Companies Inc. and Salix Pharmaceuticals have announced that they will be presenting the results of an analysis of Xifaxan (rifaximin) monotherapy at The American College of Gastroenterology 2024 Annual Scientific Meeting. The analysis evaluated the efficacy of Xifaxan monotherapy compared to lactulose monotherapy for reducing the risk of overt hepatic encephalopathy (OHE) recurrence … Read more